Novel FAK degradation compounds and their uses
Novel FAK degraders represented by formula (I) enhance immune responses against tumors by degrading FAKs, addressing the limitations of current cancer treatments by increasing cytotoxic T-cell activity and reducing immune-suppressive cells.
JP2026522189APending Publication Date: 2026-07-07BRISTOL MYERS SQUIBB CO
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- BRISTOL MYERS SQUIBB CO
- Filing Date
- 2025-03-21
- Publication Date
- 2026-07-07
AI Technical Summary
Technical Problem
Current treatments for abnormal cell proliferation, particularly cancer, are limited in effectively targeting focal adhesion kinases (FAKs) to enhance immune response and inhibit tumor growth.
Method used
Development of novel FAK degraders represented by formula (I), which can be administered to mammals to target and degrade FAKs, thereby enhancing cytotoxic T-cell activity and reducing immune-suppressive cell populations within tumors.
Benefits of technology
The FAK degraders increase the effectiveness of immune responses against tumors by increasing cytotoxic T-cell populations and decreasing immune-suppressive cells, providing a therapeutic approach to treat abnormal cell proliferation.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026522189000001_ABST
Abstract
Compounds and compositions that reduce FAK protein concentration are provided herein. In some embodiments, the compound is of formula I: It has the structure shown in TIFF2026522189000199.tif3392. In some embodiments, the compound and composition are provided for the treatment of FAK-related diseases (e.g., cancer).
Need to check novelty before this filing date? Find Prior Art